Bioventus Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BVS research report →
Companywww.bioventus.com
Bioventus Inc. a medical device company, focuses on developing and commercializing clinical treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products.
- CEO
- Robert E. Claypoole
- IPO
- 2021
- Employees
- 930
- HQ
- Durham, NC, US
Price Chart
Valuation
- Market Cap
- $741.16M
- P/E
- 25.85
- P/S
- 1.29
- P/B
- 3.90
- EV/EBITDA
- 6.72
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 67.78%
- Op Margin
- 10.64%
- Net Margin
- 4.94%
- ROE
- 16.27%
- ROIC
- 11.77%
Growth & Income
- Revenue
- $568.09M · -0.91%
- Net Income
- $22.73M · 167.77%
- EPS
- $0.34 · 165.38%
- Op Income
- $58.55M
- FCF YoY
- 88.98%
Performance & Tape
- 52W High
- $11.25
- 52W Low
- $5.81
- 50D MA
- $9.65
- 200D MA
- $8.01
- Beta
- 0.72
- Avg Volume
- 461.98K
Get TickerSpark's AI analysis on BVS
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 1, 21 | Cowdy Philip G. | other | 2,700 |
| Feb 11, 21 | Cowdy Philip G. | other | 9,000 |
| Apr 10, 26 | Singleton Mark Leonard | other | 13,000 |
| Apr 10, 26 | Singleton Mark Leonard | other | 5,648 |
| Apr 10, 26 | Singleton Mark Leonard | other | 13,000 |
| Apr 10, 26 | CHURCH KATRINA J | other | 4,300 |
| Apr 10, 26 | CHURCH KATRINA J | other | 1,868 |
| Apr 10, 26 | CHURCH KATRINA J | other | 4,300 |
| Apr 10, 26 | D'Adamio Anthony | other | 9,925 |
| Apr 10, 26 | D'Adamio Anthony | other | 4,312 |
Our BVS Coverage
We haven't published any research on BVS yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate BVS Report →